Name: VRTX Stock Rises On Quarterly Beat As Next-Gen CF Drug Scores
Uploaded: 2024-02-05T16:54:34-05:00
Duration: 5 min
Description: Late Monday, Vertex Pharmaceuticals (VRTX) reported adjusted earnings of $4.20 per share on $2.52 billion in fourth-quarter sales. VRTX stock edged higher in late trades. X On average, analysts surveyed by FactSet expected the biotech company to earn $4.07 a share on $2.51 billion in sales. During the year-earlier period, Vertex earned $3.76 per share […]

Tag: VRTX

VRTX Stock Rises On Quarterly Beat As Next-Gen CF Drug Scores

Late Monday, Vertex Pharmaceuticals (VRTX) reported adjusted earnings of $4.20 per share on $2.52 billion in fourth-quarter sales. VRTX stock edged higher in late trades. X On average, analysts surveyed by FactSet expected the biotech company to earn $4.07 a share on $2.51 billion in sales. During the year-earlier period, Vertex earned $3.76 per share […]

CRSP Stock Dips Despite Snagging A Second Gene-Editing OK; VRTX Stock Continues On Its Warpath

Crispr Therapeutics (CRSP) won its second gene-editing approval on Tuesday — two months ahead of expectations. But CRSP stock slipped at the close. X The Food and Drug Administration signed off on Crispr’s drug, Casgevy, for patients age 12 and older with beta thalassemia. Crispr developed Casgevy with Vertex Pharmaceuticals (VRTX). Beta thalassemia is an […]